/
Novavax, Inc., together with our wholly owned subsidiaries, tackles some of the world s most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M adjuvant and protein-based nanoparticles. Our corporate growth strategy focuses on maximizing the impact of our cutting-edge technology by forging partnerships for our Matrix-M…
Margins and capital returns are both well above average: 40.30% operating margin, ROIC at 166.54%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 64.7% YoY with margins expanding 76.8pp.
Negative free cash flow of -$250M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$596M
▲ +64.7% YoY
Net Income (TTM)
-$88M
▲ +334.8% YoY
Op. Margin
-13.10%
▲ +76.8pp YoY
ROIC
-22.65%
▲ +231.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$97M
▼ -149.4% YoY
Op. Cash Flow (TTM)
-$92M
▼ -180.3% YoY
Net Debt
-$495M
Net Cash Position
Cash & Equiv.
$790M
5Y CAGR: +18.8%
Continue Research